BCL2 and Infertility: There is no data about the infertility risk of idelalisib, the PI3K inhibitor approved for relapsed/refractory FL, as well as of the targeted drugs polatuzumab vedotin, the BCL-2 inhibitor venetoclax, and the Bruton’s tyrosine kinase inhibitors ibrutinib, zanubrutinib, acalabrutinib and pirtobrutinib (40).